Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals

Digestive and Liver Disease

Volumn 46, Issue 8, 2014, Pages 720-725

  de Keyser, Catherine E ^a,b   Koehler, Edith M ^a   Schouten, Jeoffrey N L ^a   Visser, Loes E ^a,c   Hofman, Albert ^a   Janssen, Harry L A ^a,d   Stricker, Bruno H ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Health Care Inspectorate   (Netherlands)

^c Hospital Pharmacist/Clinical Pharmacologist   (Netherlands)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Body mass index; HMG CoA reductase inhibitors; Metabolic syndrome; Steatosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ECHOGRAPHY; NETHERLANDS; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PROSPECTIVE STUDY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NETHERLANDS; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PREVALENCE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84904739823     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.04.002     Document Type: Article

References (49)

1. Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine 2002, 346:1221-1231.
2. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
3. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
4. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005, 41:690-695.
5. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. Journal of Hepatology 2007, 47:135-141.
6. Argo C.K., Loria P., Caldwell S.H., et al. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology 2008, 48:662-669.
7. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006, 44:466-471.
8. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010, 52:1156-1161.
9. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine 2010, 363:1341-1350.
10. Koehler E.M., Schouten J.N., Hansen B.E., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. Journal of Hepatology 2012, 57:1305-1311.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine 1998, 339:1349-1357.
13. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research 1992, 33:1569-1582.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Journal of American Medical Association 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
16. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995, 333:1301-1307.
17. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. CDS Review 2013, 1:CD004816.
18. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. British Medical Journal 2009, 338:b2376.
19. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics 2006, 80:565-581.
20. Briel M., Nordmann A.J., Bucher H.C. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Lipidology 2005, 16:601-605.
21. Tolman K.G. The liver and lovastatin. American Journal of Cardiology 2002, 89:1374-1380.
22. Parra J.L., Reddy K.R. Hepatotoxicity of hypolipidemic drugs. Clinics in Liver Disease 2003, 7:415-433.
23. Oms P., Assie N., Bruniquel F., et al. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate. Pharmacology and Toxicology 1995, 77:391-396.
24. Horsmans Y., Desager J.P., Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacology and Toxicology 1990, 67:336-339.
25. Caldwell S.H., Zaidman J.S., Hespenheide E.E. The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. Pharmacoepidemiology and Drug Safety 2003, 12:303-306.
26. Complete ATC index 2010. WHO. Collaborating Centre for Drugs Statistics Methodology. Available from: [Accessed 27.02.14]. http://www.whocc.no/atc_ddd_index.
27. Hofman A., Grobbee D.E., de Jong P.T.V.M., et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. European Journal of Epidemiology 1991, 7:403-422.
28. Hofman A., Darwish Murad S., van Duijn C.M., et al. The Rotterdam Study: 2014 objectives and design update. European Journal of Epidemiology 2013, 28:889-926.
29. Hamaguchi M., Kojima T., Itoh Y., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. American Journal of Gastroenterology 2007, 102:2708-2715.
30. Leening M.J.G., Kavousi M., Heeringa J., et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. European Journal of Epidemiology 2012, 27:173-185.
31. Bos M.J., van Rijn M.J., Witteman J.C.M., et al. Incidence and prognosis of transient neurological attacks. Journal of American Medical Association 2007, 298:2877-2885.
32. Wieberdink R.G., Ikram M.A., Hofman A., et al. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. European Journal of Epidemiology 2012, 27:287-295.
33. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
34. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
35. Bedogni G., Bellentani S., Miglioli L., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006, 6:33.
36. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 2002, 109:1125-1131.
37. Roglans N., Verd J.C., Peris C., et al. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 2002, 37:445-454.
38. Liao J.K., Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005, 45:89-118.
39. Fon Tacer K., Rozman D. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. Journal of Lipids 2011, 2011:783976.
40. Adams L.A., Lindor K.D. Nonalcoholic fatty liver disease. Annals of Epidemiology 2007, 17:863-869.
41. Stricker B.H., Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. European Journal of Epidemiology 2010, 25:245-251.
42. Horlander J.C., Kwok P.Y., Cummings O.W. Atorvastatin for the treatment of NASH [Abstract]. Gastroenterology 2001, 120.
43. Rallidis L.S., Drakoulis C.K., Parasi A.S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004, 174:193-196.
44. FDA Drug Safety Communication Important safety label changes to cholesterol-lowering statin drugs February 28, 2012.
45. Nseir W., Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Current Atherosclerosis Reports 2013, 15:305.
46. Athyros V.G., Katsiki N., Karagiannis A., et al. Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs 2013, 22:1089-1093.
47. Nseir W., Mograbi J., Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Digestive Diseases and Sciences 2012, 57:1773-1781.
48. Rocha V.Z., Folco E.J. Inflammatory concepts of obesity. International Journal of Inflammation 2011, 2011:529061.
49. Hernaez R., Lazo M., Bonekamp S., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011, 54:1082-1090.